The Lancet article says that one patient died of complications with the transplant procedure, and this was Phase 2. I'm in pharma, not stem cells, but if a patient died due to treatment, the project would be killed. Perhaps the transplant procedure is well-understood along with its risks (I assume you have to transplant into the CNS?), but even oncology drugs aren't allowed to kill patients anymore.